Cutera, Inc. (CUTR) Q3 2024 Earnings Call Transcript Summary
Cutera, Inc. (CUTR) Q3 2024 Earnings Call Transcript Summary
The following is a summary of the Cutera, Inc. (CUTR) Q3 2024 Earnings Call Transcript:
以下是古特拉公司(Cutera, Inc.)2024年第三季度業績會議記錄摘要:
Financial Performance:
財務表現:
Cutera reported a revenue of $32.5 million in Q3 2024, a decrease compared to $46.5 million in Q3 2023.
Non-GAAP gross profit for Q3 2024 was $3.7 million, with a gross margin rate of 11.5%, compared to 19.3% in Q3 2023.
Non-GAAP operating expenses for Q3 2024 were $34.7 million, a decrease from $39.8 million in the same period last year.
The company ended the quarter with $59.0 million in cash, cash equivalents, and restricted cash.
Cutera報告2024年第三季度營業收入爲3250萬美元,較2013年第三季度的4650萬美元有所下降。
2024年第三季度非通用會計原則毛利潤爲370萬美元,毛利率爲11.5%,較2013年第三季度的19.3%有所下降。
2024年第三季度非通用會計原則營業費用爲3470萬美元,較去年同期的3980萬美元有所下降。
公司以5900萬美元的現金、現金等價物和限制性現金結束了本季度。
Business Progress:
業務進展:
Cutera is focusing on improving service and inventory management, with a significant reduction in service backlog and improved service response times.
The company is continuing to roll out AviClear globally, now available in 25 countries with positive utilization trends.
New sales rep certification processes and Cutera Academy programs are in place to boost productivity and relaunch efforts.
Partnership with L'Oreal's SkinCeuticals in Japan represents a strategic move to penetrate new markets.
古特拉正專注於改善服務和庫存管理,在服務積壓和服務響應時間得到顯著減少的情況下。
公司正在全球推出AviClear,目前已在25個國家上市,並呈現出積極的利用趨勢。
新的銷售代表認證流程和Cutera academy項目已經實施,旨在提高生產力和重啓努力。
與L'Oreal旗下的SkinCeuticals合作進入日本市場代表了一個戰略性舉措,旨在打入新市場。
Opportunities:
機會:
The international launch of AviClear has been successful, and Cutera plans to focus future efforts on expanding and supporting its global presence.
AviClear的國際推出取得了成功,Cutera計劃將未來努力集中在擴大和支持其全球業務。
Risks:
風險:
Continued macroeconomic pressures and a lower demand for capital equipment purchases present ongoing challenges for revenue growth.
持續的宏觀經濟壓力和對資本設備購買需求的下降爲營業收入增長帶來持續挑戰。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示:如需更全面的詳情,請參閱投資人關係網站。本文僅供投資者參考,不作任何指引或建議。
譯文內容由第三人軟體翻譯。